Spevatamig

DB18471InvestigationalProtein Based Therapies

PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47).

Mechanism: Pharmacologically active on Claudin-18 and Leukocyte surface antigen CD47
Curator reviewed
Code names: PT-886

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Spevatamig, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.